#CII4Health @CII4Health

CII welcomes this development as a positive signal towards a more predictable and growth-oriented trade framework. This can serve as a catalyst for advancing a comprehensive bilateral trade agreement, incl. resolution of non-tariff barriers, regulatory alignment & enhanced access

India–US Trade From a pharmaceutical perspective, the tariff rationalisation improves cost competitiveness for Indian formulations and APIs in the US market and creates a conducive environment for deeper US–India collaboration in pharma manufacturing and innovation.

India-US Trade:Tariff Reduction to 18% The announcement by President Trump and PM Modi on a significant reduction in US reciprocal tariffs on Indian goods from 50% to 18% marks an important step forward in strengthening bilateral trade relations #IndiaUSRelations #CII

“The pharmaceutical sector has always been a catalyst for human progress. Now, we are equally committed to advancing a biopositive future where innovation and responsibility move hand in hand,” shares Dr. Rajesh Jain, Chairman, CII National Committee on Biotechnology & MD, @PanaceaBiotec, as he invites the industry to the 7th CII Pharma & Lifesciences Summit. @DrRajeshPanacea #CIIPharmaAndLifesciencesSummit #CII4Pharma #CII4Lifesciences @CII4Health

The 7th CII Pharma & Lifesciences Summit will convene leaders, policymakers and innovators to explore theme of “Progress, Promise and the Planet: Unlocking Sustainable Growth in Indian Pharma & Life Sciences.” Join us on 12 December 2025 in New Delhi for insights on sustainable practices, talent, technology, ethical trials and good governance. #CIIPharmaAndLifesciencesSummit #CII4Pharma #CII4Lifesciences @CII4Health @DrJitendraSingh @PanaceaBiotec @drreddys @AbbottNews @BioconBiologics @SunPharma_Live @Bayer @BSV_Global @LupinGlobal @Pharma_Mankind @DeloitteIndia @vohglobal

keyboard_arrow_left Previous keyboard_arrow_right Next

Today’s topic ‘Progress, Promise and Planet - Unlocking Sustainable Growth in Indian Pharma and Life Sciences’ is basically saying that with access and affordability, which were always the theme, we are now talking about accountability, towards the world, the planet, the people, the human world and that accountability should drive us further as we think about better healthcare and growth, and that is the big change that we are talking about today. -Sanjiv Navangul, Managing Director & Chief Executive Officer, Bharat Serums & Vaccines Limited (A Mankind Group Company) at the 7th #CIIPharmaAndLifesciencesSummit #CII4Pharma #CII4Lifesciences @CII4Health

We must ensure as a collective leadership that the industry leads and remains committed to leading through innovation, sustainability and digital transformation. We firmly believe that the Government must continue to enable bold experimentation, regulators must remain partners in progress, academia must keep driving the discoveries of tomorrow and global partners must collaborate with India as co-creators, not merely as consumers. The next two decades will shape India into a true life sciences powerhouse driven by our science, our scale, our sustainability efforts, our digital transformation and our human commitment. - Dr Rajesh Jain, Chairman, CII National Committee on Biotechnology & Chairman & Managing Director, @PanaceaBiotec, at the 7th #CIIPharmaAndLifesciencesSummit #CII4Pharma #CII4Lifesciences @DrRajeshPanacea @CII4Health

A key transformation for the pharma industry is that while we were once primarily retailers, we are now creating innovations of our own. A recent example made possible with the active support of the Government of India is the development of Naphithromycin, the first-ever indigenous antibiotic, highly effective in treating resistant respiratory infections. Today we are exporting preventive healthcare. It is a complete 360 transformation, considering India was not taken seriously as healthcare provider. - Dr Jitendra Singh, Minister Of State (Independent Charge) of The Ministry of Science and Technology; Minister of State (Independent Charge) of The Ministry of Earth Sciences; Minister of State in the Prime Minister’s Office; Minister Of State in the Ministry of Personnel, Public Grievances and Pensions; Minister of State in the Department of Atomic Energy and Minister of State in the Department of Space, at the 7th #CIIPharmaAndLifesciencesSummit @DrJitendraSingh #CII4Pharma #CII4Lifesciences

We must find value addition, and that comes from innovation. We should focus on innovation and increase our spending on R&D to become a global power in pharma by 2047. What we require is a very strong regulatory system that builds trust in the minds of patients not only in India but across the globe. Ultimately, we must come together to find solutions and develop a regulatory framework unique to our country, grounded in the principles of global convergence, so that we can continue providing quality products at affordable prices and produce innovative products. -Dr Chandrashekhar Ranga, Joint Drugs Controller General of India (JDCGI) Central Drugs Standard Control Organization (CDSCO), at the 7th #CIIPharmaAndLifesciencesSummit @CDSCO_INDIA_INF #CII4Pharma #CII4Lifesciences

Sustainability is a composite of environmental responsibility and health equity, which is a resilience strategy. Companies, to be better positioned and remain globally competitive, must invest early in climate-smart operations, renewable energy, greener processes, and responsible supply chains. Equitable access in pharma is equally important for defining long-term sustainability. There are three ways in which access becomes a sustainability accelerator: partnerships with government to address public health issues, industry and peer-led partnerships to expand access to healthcare, and affordability mechanisms for patients for access to drugs at a larger level. Companies that excel in both will define the future of India and global pharma.-Shweta Rai, Managing Director-India and Country Division Head of South Asia Bayer Pharmaceutical, at the 7th #CIIPharmaAndLifesciencesSummit #CII4Pharma #CII4Lifesciences

Address at the Confederation of Indian Industry (CII) Pharma & Life Sciences Summit 2025 #NewDelhi: "Artificial Intelligence (AI) based diagnostic models are reducing time for various procedures like, for example, culture testing from days to minutes, and telemedicine projects driven by AI are extending medical services to remote villages in local dialects, significantly improving patient confidence and outcomes. Judicious use of AI can be a boon for healthcare and pharma sectors. One of the important transformations under PM @NarendraModi has been that the government reaches out to the industry with equal enthusiasm, reflecting a true whole-of-government plus whole-of-industry approach. The government is actively partnering with the private sector in frontier areas such as gene therapy, biotechnology, and vaccine development".

keyboard_arrow_left Previous keyboard_arrow_right Next

Registration Link: lnkd.in/d6P7Bzm6 @CII4Health #CIIPharmaAndLifesciencesSummit

Join in for the 7th CII Pharma & Life Sciences Summit 2025 on 12 December 2025 in New Delhi. Witness India’s senior industry leaders, policymakers,

The CII Pharma & Life Sciences Summit 2025 is set to bring together senior industry leaders, policymakers, researchers, and innovators to deliberate on how Indian pharma and Life sciences can grow sustainably while staying globally competitive, while exploring the theme 'Progress, Promise and the Planet: Unlocking Sustainable Growth in Indian Pharma & Life Sciences.' Join in for diverse perspectives on sustainable business practices, talent development, tech-driven pharma sustainability, ethical clinical trials, environmental regulations, and good governance on 12 December 2025 in New Delhi. Registration Link: lnkd.in/d6P7Bzm6 @CII4Health #CIIPharmaAndLifesciencesSummit

#CII4Health #CIIHealthSummit2025 #HealthInnovation #DigitalHealthIndia #FutureOfHealthcare #HealthTech #PublicPrivateHealth #SeniorCare #CIISeniorCareConclave

Private sector stakeholders need to account for these dynamics when integrating AI into healthcare and broader systems. -Mr Madhukar Kumar Bhagat, Joint Secretary, Ministry of Health & Family Welfare

The government’s approach to AI and “human in the loop” must be understood in context, recognising both institutional structures and individual perspectives. Adoption depends on relative parameters such as efficiency and trust: if AI demonstrates higher diagnostic efficiency

-Dr Krithika Rangarajan, Associate Professor, Radiology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital (IRCH), @aiims_nd #CII4Health #CIIHealthSummit2025 #HealthInnovation #DigitalHealthIndia #FutureOfHealthcare #HealthTech #PublicPrivateHealth #SeniorCare

By recording doctor-patient conversations, transcribing them, and providing clearer, more interpretable insights, technology can enhance communication and understanding, showing that innovation can complement, not replace, human care.

As we integrate more data points, healthcare inevitably becomes more complex, requiring continual evolution of practice rather than rendering professionals obsolete. Technology should be embraced while keeping patients and communities at the centre, creating systems that enhance